Walleye Capital
DNTH icon

Walleye Capital’s Dianthus Therapeutics DNTH Stock Holding History

Walleye Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Sell
17,881
-135,704
-88% -$11.9M 0.01% 1634
2026
Q1 		$12.9M Sell
153,585
-52,230
-25% -$3.02M 0.05% 313
2025
Q4 		$8.48M Buy
205,815
+64,686
+46% +$2.51M 0.03% 761
2025
Q3 		$5.55M Buy
141,129
+114,996
+440% +$2.94M 0.02% 867
2025
Q2 		$487K Sell
26,133
-80,798
-76% -$1.52M ﹤0.01% 2656
2025
Q1 		$1.94M Buy
106,931
+24,041
+29% +$530K 0.01% 1439
2024
Q4 		$1.81M Buy
82,890
+52,890
+176% +$1.36M ﹤0.01% 1870
2024
Q3 		$821K Buy
+30,000
New +$836K ﹤0.01% 2844
2024
Q2 		– Sell
-190,266
Closed -$5.71M – 5675
2024
Q1 		$5.71M Buy
+190,266
New +$4.14M 0.01% 1202
2022
Q2 		– Sell
-2,584
Closed -$120K – 2454
2022
Q1 		$120K Buy
2,584
+835
+48% +$45.6K ﹤0.01% 1692
2021
Q4 		$124K Buy
+1,749
New +$176K ﹤0.01% 1615

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Walleye Capital's DNTH Position: Q2 2026 in Review

Walleye Capital reduced its Dianthus Therapeutics (DNTH) stake by 88% in Q2 2026, selling an estimated $11.9M and leaving 17,881 shares worth $1.74M. The position accounts for 0.01% of the portfolio, ranked #1634.

Walleye Capital first reported a position in DNTH in Q4 2021 and has held it in 11 quarters since. The position peaked at $12.9M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Walleye Capital held 17,881 shares of Dianthus Therapeutics worth $1.74M as of Q2 2026.
  • Walleye Capital sold 135,704 Dianthus Therapeutics shares in Q2 2026, an estimated $11.9M.
  • Dianthus Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1634 holding.
  • Walleye Capital first reported a position in Dianthus Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Walleye Capital's Dianthus Therapeutics position peaked at $12.9M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.